Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial-Reference-Cited by-同舟云学术

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial

Published:2017-07 Issue:7 Volume:2 Page:494-500
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Welzel Tania M,Asselah Tarik,Dumas Emily O,Zeuzem Stefan,Shaw David,Hazzan Rawi,Forns Xavier,Pilot-Matias Tami,Lu Wenjing,Cohen Daniel E,Feld Jordan J

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference24 articles.

1. Global distribution and prevalence of hepatitis C virus genotypes;Messina;Hepatology,2015

2. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis;van der Meer;JAMA,2012

3. EASL Recommendations on Treatment of Hepatitis C 2015;J Hepatol,2015

4. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus;Panel;Hepatology,2015

5. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives;Asselah;Liver Int,2016

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals;Expert Opinion on Pharmacotherapy;2024-05-02

2. Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C;Russian Journal of Gastroenterology, Hepatology, Coloproctology;2023-06-04

3. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C;World Journal of Gastroenterology;2023-02-14

4. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients;World Journal of Gastroenterology;2022-12-07

5. Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis;Journal of Viral Hepatitis;2022-04-06